{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:20:06Z","timestamp":1788967206925,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Immunisation Division of the Australian Government Department of Health, Disability and Ageing."},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40273-026-01601-8","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:54:45Z","timestamp":1772884485000},"page":"761-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of Immunising Interventions to Reduce Respiratory Syncytial Virus Disease Burden in Infants in Australia"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-0809","authenticated-orcid":false,"given":"Julian B.","family":"Carlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-6886","authenticated-orcid":false,"given":"Adrian J.","family":"Marcato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-1200","authenticated-orcid":false,"given":"Cyan Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4568-2012","authenticated-orcid":false,"given":"Robert","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3663-8802","authenticated-orcid":false,"given":"Kylie S.","family":"Carville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6041-2993","authenticated-orcid":false,"given":"Xinghui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-5329","authenticated-orcid":false,"given":"Victoria L.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0600-4569","authenticated-orcid":false,"given":"Violeta","family":"Spirkoska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-9835","authenticated-orcid":false,"given":"Patricia T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0076-3123","authenticated-orcid":false,"given":"David J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-2209","authenticated-orcid":false,"given":"Natalie","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9774-1961","authenticated-orcid":false,"given":"Jodie","family":"McVernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"10389","key":"1601_CR1","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S0140-6736(23)00811-5","volume":"401","author":"C Rosas-Salazar","year":"2023","unstructured":"Rosas-Salazar C, Chirkova T, Gebretsadik T, Chappell JD, Peebles RS, Dupont WD, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet. 2023;401(10389):1669\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(23)00811-5.","journal-title":"Lancet"},{"issue":"10340","key":"1601_CR2","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li Y, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(22)00478-0.","journal-title":"Lancet"},{"issue":"10","key":"1601_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.5694\/mja2.50159","volume":"210","author":"GL Saravanos","year":"2019","unstructured":"Saravanos GL, Sheel M, Homaira N, Dey A, Brown E, Wang H, et al. Respiratory syncytial virus-associated hospitalisations in Australia, 2006\u20132015. Med J Aust. 2019;210(10):447\u201353. https:\/\/doi.org\/10.5694\/mja2.50159.","journal-title":"Med J Aust"},{"issue":"16","key":"1601_CR4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2216480.","journal-title":"N Engl J Med"},{"issue":"5","key":"1601_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1913556.","journal-title":"N Engl J Med"},{"issue":"9","key":"1601_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2110275.","journal-title":"N Engl J Med"},{"key":"1601_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100829","author":"D Hodgson","year":"2024","unstructured":"Hodgson D, Wilkins N, van Leeuwen E, Watson CH, Crofts J, Flasche S, et al. Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination. Lancet Region Health Eur. 2024. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100829.","journal-title":"Lancet Region Health Eur"},{"key":"1601_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126651","volume":"46","author":"AL Nazareno","year":"2025","unstructured":"Nazareno AL, Wood JG, Muscatello DJ, Homaira N, Hogan AB, Newall AT. Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: a dynamic and economic modelling analysis. Vaccine. 2025;46:126651. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126651.","journal-title":"Vaccine"},{"issue":"5","key":"1601_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40273-025-01469-0","volume":"43","author":"F Zeevat","year":"2025","unstructured":"Zeevat F, van der Pol S, Kieffer A, Postma MJ, Boersma C. Cost-effectiveness analysis of nirsevimab for preventing respiratory syncytial virus-related lower respiratory tract disease in Dutch infants: an analysis including all-infant protection. Pharmacoeconomics. 2025;43(5):569\u201382. https:\/\/doi.org\/10.1007\/s40273-025-01469-0.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1601_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41467-020-20544-y","volume":"12","author":"D Mistry","year":"2021","unstructured":"Mistry D, et al. Inferring high-resolution human mixing patterns for disease modeling. Nat Commun. 2021;12(1):323. https:\/\/doi.org\/10.1038\/s41467-020-20544-y.","journal-title":"Nat Commun"},{"issue":"45","key":"1601_CR11","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1016\/j.vaccine.2017.09.043","volume":"35","author":"AB Hogan","year":"2017","unstructured":"Hogan AB, Campbell PT, Blyth CC, Lim FJ, Fathima P, Davis S, et al. Potential impact of a maternal vaccine for RSV: a mathematical modelling study. Vaccine. 2017;35(45):6172\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.043.","journal-title":"Vaccine"},{"issue":"1","key":"1601_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12916-020-01802-8","volume":"18","author":"D Hodgson","year":"2020","unstructured":"Hodgson D, Pebody R, Panovska-Griffiths J, Baguelin M, Atkins KE. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis. BMC Med. 2020;18(1):348. https:\/\/doi.org\/10.1186\/s12916-020-01802-8.","journal-title":"BMC Med"},{"issue":"6","key":"1601_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/archpedi.1986.02140200053026","volume":"140","author":"WP Glezen","year":"1986","unstructured":"Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child (1960). 1986;140(6):543\u20136. https:\/\/doi.org\/10.1001\/archpedi.1986.02140200053026.","journal-title":"Am J Dis Child (1960)"},{"issue":"6","key":"1601_CR14","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall CB, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588\u201398. https:\/\/doi.org\/10.1056\/NEJMoa0804877.","journal-title":"N Engl J Med"},{"issue":"6","key":"1601_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/INF.0000000000004288","volume":"43","author":"SA Lim","year":"2024","unstructured":"Lim SA, et al. Risk factors and clinical prognosis associated with RSV-ALRI intensive care unit admission in children $$<$$2 years of age: a multicenter study. Pediatr Infect Dis J. 2024;43(6):511. https:\/\/doi.org\/10.1097\/INF.0000000000004288.","journal-title":"Pediatr Infect Dis J"},{"issue":"26","key":"1601_CR16","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","volume":"389","author":"SB Drysdale","year":"2023","unstructured":"Drysdale SB, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2309189.","journal-title":"N Engl J Med"},{"issue":"8","key":"1601_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","volume":"24","author":"S Ares-G\u00f3mez","year":"2024","unstructured":"Ares-G\u00f3mez S, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024;24(8):817\u201328. https:\/\/doi.org\/10.1016\/S1473-3099(24)00215-9.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1601_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/vaccines12040383","volume":"12","author":"G Ezpeleta","year":"2024","unstructured":"Ezpeleta G, et al. Effectiveness of nirsevimab immunoprophylaxis administered at birth to prevent infant hospitalisation for respiratory syncytial virus infection: a population-based cohort study. Vaccines. 2024;12(4):383. https:\/\/doi.org\/10.3390\/vaccines12040383.","journal-title":"Vaccines"},{"issue":"6","key":"1601_CR19","doi-asserted-by":"publisher","first-page":"2400046","DOI":"10.2807\/1560-7917.ES.2024.29.6.2400046","volume":"29","author":"M L\u00f3pez-Lacort","year":"2024","unstructured":"L\u00f3pez-Lacort M, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Eurosurveillance. 2024;29(6):2400046. https:\/\/doi.org\/10.2807\/1560-7917.ES.2024.29.6.2400046.","journal-title":"Eurosurveillance"},{"key":"1601_CR20","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7309a4","author":"HL Moline","year":"2024","unstructured":"Moline HL. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season\u2014new vaccine surveillance network, October 2023\u2013February 2024. MMWR Morbid Mortal Wkly Rep. 2024. https:\/\/doi.org\/10.15585\/mmwr.mm7309a4.","journal-title":"MMWR Morbid Mortal Wkly Rep"},{"issue":"5","key":"1601_CR21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41591-023-02316-5","volume":"29","author":"D Wilkins","year":"2023","unstructured":"Wilkins D, et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat Med. 2023;29(5):1172\u20139. https:\/\/doi.org\/10.1038\/s41591-023-02316-5.","journal-title":"Nat Med"},{"key":"1601_CR22","unstructured":"Australian Government Department of Health and Aged Care. Immunisation for pregnancy [text]. Australian Government Department of Health and Aged Care. https:\/\/www.health.gov.au\/topics\/immunisation\/when-to-get-vaccinated\/immunisation-for-pregnancy."},{"key":"1601_CR23","unstructured":"Australian Government Department of Health and Aged Care. PBAC guidelines version 5.0. https:\/\/pbac.pbs.gov.au\/."},{"key":"1601_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100629","volume":"28","author":"A Shoukat","year":"2023","unstructured":"Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. Lancet Region Health Am. 2023;28:100629. https:\/\/doi.org\/10.1016\/j.lana.2023.100629.","journal-title":"Lancet Region Health Am"},{"key":"1601_CR25","unstructured":"Independent Health and Aged Care Pricing Authority. National Hospital Cost Data Collection (NHCDC) public sector 2021\u201322 (round 26). urlhttps:\/\/www.ihacpa.gov.au\/resources\/national-hospital-cost-data-collection-nhcdc-public-sector-2021-22."},{"key":"1601_CR26","unstructured":"Centers for Disease Control. Current CDC Vaccine Price List. Centers for Disease Control; 2025. https:\/\/www.cdc.gov\/vaccines-for-children\/php\/awardees\/current-cdc-vaccine-price-list.html."},{"key":"1601_CR27","unstructured":"Australia Institute. Comparing drug prices in Australia and the USA: the implications of the US-Australia free trade agreement. Australia Institute; 2003. https:\/\/australiainstitute.org.au\/report\/comparing-drug-prices-in-australia-and-the-usa-the-implications-of-the-us-australia-free-trade-agreement\/."},{"issue":"3","key":"1601_CR28","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11136-023-03558-z","volume":"33","author":"L Redwood","year":"2024","unstructured":"Redwood L, Currow D, Kochovska S, Thomas SJ. Australian population norms for health-related quality of life measured using the EQ-5D-5L, and relationships with sociodemographic characteristics. Qual Life Res. 2024;33(3):721\u201333. https:\/\/doi.org\/10.1007\/s11136-023-03558-z.","journal-title":"Qual Life Res"},{"issue":"1","key":"1601_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23. https:\/\/doi.org\/10.1186\/s12916-021-02204-0.","journal-title":"BMC Med"},{"key":"1601_CR30","unstructured":"Department of Health and Aged Care. The Australian immunisation handbook. Respiratory syncytial virus. https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccine-preventable-diseases\/respiratory-syncytial-virus-rsv."},{"issue":"3","key":"1601_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40273-020-00991-7","volume":"39","author":"M Treskova","year":"2021","unstructured":"Treskova M, Pozo-Martin F, Scholz S, Sch\u00f6nfeld V, Wichmann O, Harder T. Assessment of the effects of active immunisation against respiratory syncytial virus (RSV) using decision-analytic models: a systematic review with a focus on vaccination strategies, modelling methods and input data. Pharmacoeconomics. 2021;39(3):287\u2013315. https:\/\/doi.org\/10.1007\/s40273-020-00991-7.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1601_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jval.2022.11.014","volume":"26","author":"X Li","year":"2023","unstructured":"Li X, Hodgson D, Flaig J, Kieffer A, Herring WL, Beyhaghi H, et al. Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study. Value Health. 2023;26(4):508\u201318. https:\/\/doi.org\/10.1016\/j.jval.2022.11.014.","journal-title":"Value Health"},{"key":"1601_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101141","author":"S Nourbakhsh","year":"2021","unstructured":"Nourbakhsh S, Shoukat A, Zhang K, Poliquin G, Halperin D, Sheffield H, et al. Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: a case study of Nunavik, Canada. eClinicalMedicine. 2021. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101141.","journal-title":"eClinicalMedicine"},{"issue":"21","key":"1601_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126164","volume":"42","author":"GB Gebretekle","year":"2024","unstructured":"Gebretekle GB, et al. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants. Vaccine. 2024;42(21):126164. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126164.","journal-title":"Vaccine"},{"issue":"4","key":"1601_CR35","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/infdis\/jiy671","volume":"220","author":"N Homaira","year":"2019","unstructured":"Homaira N, Briggs N, Oei JL, Hilder L, Bajuk B, Jaffe A, et al. Association of age at first severe respiratory syncytial virus disease with subsequent risk of severe asthma: a population-based cohort study. J Infect Dis. 2019;220(4):550\u20136. https:\/\/doi.org\/10.1093\/infdis\/jiy671.","journal-title":"J Infect Dis"},{"issue":"2","key":"1601_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296685","volume":"19","author":"A Shiroshita","year":"2024","unstructured":"Shiroshita A, Gebretsadik T, Wu P, Kubilay NZ, Hartert TV. Association between age of respiratory syncytial virus infection hospitalization and childhood asthma: a systematic review. PLoS ONE. 2024;19(2):e0296685. https:\/\/doi.org\/10.1371\/journal.pone.0296685.","journal-title":"PLoS ONE"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01601-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:42:14Z","timestamp":1788964934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01601-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01601-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the National Immunisation Division of the Australian Government Department of Health, Disability and Ageing to support policy decision making. The model was parameterised using nationally aggregated patient data provided by the Department of Health, Disability and Ageing using Admitted Patient Care data supplied by the Australian Institute of Health and Welfare (AIHW). National Admitted Patient Care data (i.e. line by line unit records), collated by AIHW and supplied to the Department of Health, Disability and Ageing, were aggregated and suppressed by the Department before being provided to the authors. Approval for the use of these data for analyses and subsequent publication was granted by the Department. Clinical risk factors in early infancy were parameterised using de-identified patient data from the Royal Children\u2019s Hospital, use of which was granted by the Murdoch Children\u2019s Research Institute Ethics Committee (#37185)","order":2,"name":"Ethics","label":"Ethical Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are provided within the manuscript and supplementary information file. Code and instructions on reproducing the results in the study are available at the following repository:\n                      \n                      .","order":4,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Formal analysis (JBC, AJM, CYW); funding acquisition (JMcV); investigation (JBC, AJM, CYW); methodology (JBC, AJM, CYW, PTC, JMcV); project administration (PTC, JMcV); resources (JMcV); software (JBC, CYW, RM); supervision (PTC, DJP, NC, JMcV); validation\u2013verification (KSC, VLO, VS); visualisation (JBC, CYW); writing\u2014original draft (JBC, AJM, CYW, VLO, JMcV); writing\u2014review and editing (All).","order":5,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}